StockNews.com lowered shares of Cellectis (NASDAQ:CLLS - Free Report) from a buy rating to a hold rating in a report issued on Thursday morning.
Cellectis Stock Performance
NASDAQ:CLLS traded up $0.06 during trading hours on Thursday, reaching $1.44. 44,580 shares of the stock were exchanged, compared to its average volume of 145,409. The stock has a market capitalization of $80.04 million, a P/E ratio of -1.11 and a beta of 3.22. The firm has a 50 day simple moving average of $1.33 and a 200-day simple moving average of $1.63. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. Cellectis has a 52 week low of $1.10 and a 52 week high of $3.38.
Cellectis (NASDAQ:CLLS - Get Free Report) last announced its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.22). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The firm had revenue of $33.22 million for the quarter, compared to the consensus estimate of $5.90 million. As a group, sell-side analysts forecast that Cellectis will post -0.46 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Cellectis
A number of large investors have recently bought and sold shares of CLLS. Wells Fargo & Company MN grew its holdings in shares of Cellectis by 103.4% during the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 12,500 shares during the last quarter. B Group Inc. bought a new position in Cellectis during the 4th quarter worth $5,547,000. Finally, Millennium Management LLC acquired a new stake in Cellectis in the fourth quarter worth $962,000. Institutional investors own 63.90% of the company's stock.
About Cellectis
(
Get Free Report)
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
Further Reading
Before you consider Cellectis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellectis wasn't on the list.
While Cellectis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
